金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300233 金城医药

交易中 08-15 11:07:21

{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":18.21,"timestamp":1755227241000,"preClose":18.01,"halted":0,"volume":8353711,"delay":0,"changeRate":0.0111,"floatShares":372000000,"shares":384000000,"eps":0.3878,"marketStatus":"交易中","change":0.2,"latestTime":"08-15 11:07:21","open":18.05,"high":18.28,"low":18.03,"amount":152000000,"amplitude":0.0139,"askPrice":18.21,"askSize":89,"bidPrice":18.2,"bidSize":24,"shortable":0,"etf":0,"ttmEps":0.3878,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1755228600000},"marketStatusCode":2,"adr":0,"adjPreClose":18.01,"symbolType":"stock","openAndCloseTimeList":[[1755221400000,1755228600000],[1755234000000,1755241200000]],"highLimit":19.81,"lowLimit":16.21,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"isCdr":false,"pbRate":1.85,"roa":"--","peRate":46.957194,"roe":"0.93%","epsLYR":0.52,"committee":0.727338,"marketValue":6990000000,"turnoverRate":0.0225,"status":0,"floatMarketCap":6769000000},"requestUrl":"/m/hq/s/300233","defaultTab":"news","newsList":[{"id":"2558630631","title":"8月11日金城医药涨7.65%，大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2558630631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558630631?lang=zh_cn&edition=full","pubTime":"2025-08-11 16:26","pubTimestamp":1754900801,"startTime":"0","endTime":"0","summary":"证券之星消息，8月11日金城医药涨7.65%创60日新高，收盘报19.14元，换手率15.6%，成交量57.97万手，成交额10.91亿元。重仓金城医药的公募基金请见下表：根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A目前规模为3.97亿元，最新净值3.3186，较上一交易日上涨0.09%，近一年上涨86.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081100025852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"gpt_icon":0},{"id":"2557844915","title":"禽流感概念盘中拉升，金城医药涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557844915","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557844915?lang=zh_cn&edition=full","pubTime":"2025-08-07 09:39","pubTimestamp":1754530763,"startTime":"0","endTime":"0","summary":"08月07日，禽流感概念盘中拉升，截至09点39分，禽流感概念整体指数上涨0.81%，报1492.840点。从个股上来看，该概念的成分股中，金城医药涨5.20%，达安基因、联环药业、沃华医药涨幅居前。从资金上来看，截止发稿，禽流感概念主力净流入为-2377.12万，其中金城医药受到资金热捧，主力净流入3747.51万；拉长时间线来看，该板块近20日主力资金净流入-36.10亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080709392394d48aed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080709392394d48aed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","600513","BK0028","300233"],"gpt_icon":0},{"id":"2557034498","title":"金城医药：截至2025年7月31日公司股东总户数为37,689户","url":"https://stock-news.laohu8.com/highlight/detail?id=2557034498","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557034498?lang=zh_cn&edition=full","pubTime":"2025-08-06 11:36","pubTimestamp":1754451371,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，你好!请问截止至2025年7月31日，公司股东人数总数是多少?谢谢!金城医药回复：投资者，您好，截至2025年7月31日公司股东总户数为37,689户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080600015786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2557361890","title":"金城医药最新公告：子公司收到化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2557361890","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557361890?lang=zh_cn&edition=full","pubTime":"2025-08-05 16:58","pubTimestamp":1754384288,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司北京金城泰尔制药有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，批准乳糖酸红霉素在国内市场进行生产销售。这将进一步丰富公司产品线，提升在化学原料药领域的市场竞争力。但药品销售受国家政策、市场环境变化等综合因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500028177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"gpt_icon":0},{"id":"2556287441","title":"口含烟概念盘中跳水，金城医药跌4.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556287441","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556287441?lang=zh_cn&edition=full","pubTime":"2025-08-04 09:46","pubTimestamp":1754271983,"startTime":"0","endTime":"0","summary":"08月04日，口含烟概念盘中跳水，截至09点46分，口含烟概念整体指数下跌2.01%，报996.660点。从个股上来看，该概念的成分股中，金城医药跌4.43%，润都股份、赢合科技、小崧股份跌幅居前。从资金上来看，截止发稿，口含烟概念主力净流入为-4639.28万，其中诺邦股份受到资金热捧，主力净流入109.54万；拉长时间线来看，该板块近20日主力资金净流入-5.98亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080409462394cd90b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080409462394cd90b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","603238","BK0239","BK0247","300233"],"gpt_icon":0},{"id":"2555570888","title":"金城医药最新公告：子公司获得韩国药品进口许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2555570888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555570888?lang=zh_cn&edition=full","pubTime":"2025-07-31 17:11","pubTimestamp":1753953068,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司北京金城泰尔制药有限公司近日收到韩国食品药品安全部下发的普罗雌烯乳膏药品进口许可证。该产品为严格局部作用的雌激素，用于外阴、前庭部及阴道环部的萎缩性病变，以及由此引发的自觉症状。普罗雌烯乳膏获得韩国MFDS的药品进口许可，标志着该产品获得了在韩国的准入资格，对公司拓展韩国医药市场具有积极影响，有利于促进产品在海外市场的销售。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100027211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2554766157","title":"金城医药最新公告：金城泰尔收到磷酸奥司他韦化学原料药CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2554766157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554766157?lang=zh_cn&edition=full","pubTime":"2025-07-28 19:31","pubTimestamp":1753702261,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司金城泰尔收到欧洲药品质量管理局核准签发的磷酸奥司他韦化学原料药欧洲药典适用性证书。磷酸奥司他韦是一种选择性的流感病毒神经氨酸酶抑制剂，由罗氏公司研制开发。该证书的获得丰富了金城泰尔的产品系列，有助于其进一步扩展海外市场，提升公司在原料药市场的竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800028253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2554228827","title":"金城医药(300233)7月20日股东户数3.72万户，较上期增加10.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554228827","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554228827?lang=zh_cn&edition=full","pubTime":"2025-07-28 17:08","pubTimestamp":1753693710,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2025年7月20日公司股东户数为3.72万户，较6月10日增加3478.0户，增幅为10.31%。在化学制药行业个股中，金城医药股东户数高于行业平均水平，截至7月20日，化学制药行业平均股东户数为3.3万户。从股价来看，2025年6月10日至2025年7月20日，金城医药区间涨幅为14.87%，在此期间股东户数增加3478.0户，增幅为10.31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800022779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2554721662","title":"金城医药：公司已取得烟草专卖生产企业许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2554721662","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554721662?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:24","pubTimestamp":1753691052,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！贵公司的尼古丁袋/口含烟产品每月出货量是多少，能和大家分享下产销情况吗？金城医药回复：投资者，您好，公司已于2025年7月18日取得国家烟草专卖局下发的《烟草专卖生产企业许可证》，核定产能电子烟用烟碱不超过200.0吨/年。公司正在积极布局新型烟草领域，加快下游相关产品的市场推广。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800021110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2554580721","title":"金城医药：公司谷胱甘肽年产能400余吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2554580721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554580721?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:21","pubTimestamp":1753690874,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年7月公司谷胱甘肽年产能是多少吨？公司规划扩产产能是多少？什么时候开始建设扩产谷胱甘肽，预计投产时间是什么时候？公司医用级谷胱甘肽2025年7月销售均价与去年同期有多大变化？金城医药回复：投资者，您好，公司谷胱甘肽年产能400余吨，目前能够满足市场需求；产品价格受多种因素影响，根据市场需求定价。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072800021045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2553214202","title":"金城医药：公司新型烟草领域主要以提取及合成烟碱为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2553214202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553214202?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:16","pubTimestamp":1753319770,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！目前公司尼古丁袋/口含烟有新增客户和订单吗，公司在新型烟草这个赛道的定位是怎样的。金城医药回复：投资者，您好，公司新型烟草领域主要以提取及合成烟碱为主并逐步拓展开发其他相关产品，如香精香料、尼古丁疗法和减害化产品等。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400006049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2553221623","title":"金城医药：VGX-3100项目新增适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2553221623","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553221623?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:03","pubTimestamp":1753319004,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药07月23日在投资者关系平台上答复投资者关心的问题。公司参与的VGX-3100项目针对宫颈癌前病变处于三期临床试验阶段，其新增适应症阴道癌和肛门癌前病变已收到国家药监局下发的《药物临床试验批准通知书》。药品研发周期长、环节多，从研发至上市会受到一些不确定性因素影响，敬请广大投资者注意投资风险！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400005877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","BK0028","BK1583","BK0239","300233","03347"],"gpt_icon":0},{"id":"2553447426","title":"口含烟概念盘中跳水，金城医药跌4.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553447426","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553447426?lang=zh_cn&edition=full","pubTime":"2025-07-21 09:38","pubTimestamp":1753061931,"startTime":"0","endTime":"0","summary":"07月21日，口含烟概念盘中跳水，截至09点38分，口含烟概念整体指数下跌1.10%，报996.030点。从个股上来看，该概念的成分股中，金城医药跌4.84%，润都股份、小崧股份跌幅居前。从资金上来看，截止发稿，口含烟概念主力净流入为-5890.99万，其中诺邦股份受到资金热捧，主力净流入72.26万；拉长时间线来看，该板块近20日主力资金净流入-6.48亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721093851a457eea1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721093851a457eea1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","300233","BK0239","603238","BK0247"],"gpt_icon":0},{"id":"2552633594","title":"7月18日金城医药涨9.38%，大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2552633594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552633594?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:22","pubTimestamp":1752826936,"startTime":"0","endTime":"0","summary":"证券之星消息，7月18日金城医药涨9.38%创60日新高，收盘报19.0元，换手率18.98%，成交量70.53万手，成交额13.0亿元。重仓金城医药的公募基金请见下表：根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A目前规模为3.17亿元，最新净值3.133，较上一交易日上涨0.8%，近一年上涨80.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800025313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2552523824","title":"创新药概念股拉升 欧林生物、金城医药涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552523824","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552523824?lang=zh_cn&edition=full","pubTime":"2025-07-18 13:57","pubTimestamp":1752818241,"startTime":"0","endTime":"0","summary":"人民财讯7月18日电，创新药概念股拉升，欧林生物、金城医药涨超10%，昂利康、康辰药业、汉商集团涨停。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718135721a6b15730&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718135721a6b15730&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688319","600774","BK0028","300233","BK0239","BK0209","603590","159992"],"gpt_icon":0},{"id":"2552896459","title":"金城医药(300233.SZ)子公司烟草专卖生产企业许可证续期及变更 电子烟用烟碱核定产能增加至不超200吨/年","url":"https://stock-news.laohu8.com/highlight/detail?id=2552896459","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552896459?lang=zh_cn&edition=full","pubTime":"2025-07-18 11:53","pubTimestamp":1752810804,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药(300233.SZ)发布公告，公司之全资子公司山东金城医药化工有限公司(以下简称“金城医化”)于2025年7月18日收到国家烟草专卖局下发的《烟草专卖生产企业许可证》(电子烟用烟碱生产企业)。本次下发的《烟草专卖生产企业许可证》将有效期延长至2028年06月30日，并对原许可证的相关内容进行了变更。本次金城医化新获得的《烟草专卖生产企业许可证》有效期限延长至2028年06月30日，电子烟用烟碱核定产能增加至不超过200吨/年，将对公司业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1319330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300233","BK1580","BK0028","06969","BK1589","BK1242"],"gpt_icon":0},{"id":"2546379089","title":"6月27日金城医药涨10.52%，大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2546379089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546379089?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:28","pubTimestamp":1751012904,"startTime":"0","endTime":"0","summary":"证券之星消息，6月27日金城医药涨10.52%，收盘报17.02元，换手率17.44%，成交量64.84万手，成交额11.02亿元。重仓金城医药的公募基金请见下表：根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A目前规模为3.17亿元，最新净值2.968，较上一交易日下跌0.07%，近一年上涨61.71%。该公募基金现任基金经理为苏秉毅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062700026683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2546787899","title":"金城医药(300233.SZ)：泊沙康唑原料药取得FDA注册批准函","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787899","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546787899?lang=zh_cn&edition=full","pubTime":"2025-06-26 19:31","pubTimestamp":1750937490,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药(300233.SZ)公告，公司全资子公司山东金城昆仑药业有限公司收到美国食品药品监督管理局(简称“FDA”)签发的泊沙康唑原料药注册批准函 DMF First Adequate Letter(简称“FA Letter”)。公告显示，泊沙康唑是由伊曲康唑衍生出的第二代三唑类抗真菌药，用于成人患者的侵袭性曲霉病的治疗和预防13岁和13岁以上因重度免疫缺陷而导致侵袭性曲霉菌和念珠菌感染风险增加的患者，例如接受造血干细胞移植(HSCT)后发生移植物抗宿主病(GVHD)的患者或化疗导致长时间中性粒细胞减少症的血液系统恶性肿瘤患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1310323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金城医药(300233.SZ)：泊沙康唑原料药取得FDA注册批准函","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2546903220","title":"金城医药：VGX-3100项目新增适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2546903220","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546903220?lang=zh_cn&edition=full","pubTime":"2025-06-26 08:54","pubTimestamp":1750899256,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药06月25日在投资者关系平台上答复投资者关心的问题。公司参与的VGX-3100项目针对宫颈癌前病变处于三期临床试验阶段，其新增适应症阴道癌和肛门癌前病变已收到国家药监局下发的《药物临床试验批准通知书》。药品研发周期长、环节多，从研发至上市会受到一些不确定性因素影响，敬请广大投资者注意投资风险！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062600006609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1576","BK0239","300233","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2544150963","title":"金城医药收盘下跌3.25%，滚动市盈率39.12倍，总市值58.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544150963","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544150963?lang=zh_cn&edition=full","pubTime":"2025-06-19 17:41","pubTimestamp":1750326107,"startTime":"0","endTime":"0","summary":"6月19日，金城医药今日收盘15.17元，下跌3.25%，滚动市盈率PE达到39.12倍，总市值58.23亿元。从行业市盈率排名来看，公司所处的化学制药行业市盈率平均52.37倍，行业中值30.11倍，金城医药排名第102位。股东方面，截至2025年6月10日，金城医药股东户数33748户，较上次增加51户，户均持股市值35.28万元，户均持股数量2.76万股。最新一期业绩显示，2025年一季报，公司实现营业收入7.22亿元，同比-22.52%；净利润3505.48万元，同比-57.75%，销售毛利率34.17%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/19174151173179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0028","300233"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755227243904,"stockEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":0.0849},{"period":"3month","weight":0.0823},{"period":"6month","weight":0.3857},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.5312}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0461},{"period":"3month","weight":0.0888},{"period":"6month","weight":0.0955},{"period":"1year","weight":0.2862},{"period":"ytd","weight":0.0939}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37689人(较上一季度增加1.24%)","perCapita":"9862股","listingDate":"2011-06-22","address":"山东省淄博市淄川区经济开发区双山路1号","registeredCapital":"38387万元","survey":"　　山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是头孢侧链活性酯系列产品、生物制药及特色原料药系列产品、制剂产品、其他医药化工产品。报告期内，公司先后获评中国医药工业百强、山东省民营企业创新100强、淄博企业100强、淄博制造业企业100强、山东社会责任企业、淄博市绿色低碳高质量发展先进集体等多项荣誉。","listedPrice":18.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}